Portrait

Quentin Blackford joined iRhythm in 2021 and serves as the President and Chief Executive Officer. Prior to joining iRhythm, Mr. Blackford was the Chief Operating Officer at Dexcom, where he was responsible for global operations, strategic development, and strategic growth. He also served as its Chief Financial Officer. Mr. Blackford held several leadership positions at NuVasive, including Executive Vice President, Chief Financial Officer, and Head of Strategy and Corporate Integrity. Mr. Blackford worked at Zimmer Holdings, Inc. leading the organization’s Global Financial Planning and Analysis group, in addition to serving as Director of Finance and Controller of the Dental Division. Mr. Blackford has served as an independent member of the Board of Directors of Alphatec Holdings, Inc. since October 2017. He is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.

Portrait

Sara Bender joined iRhythm in 2021 as Vice President of Corporate Strategy responsible for the Silent AF initiative. In her first year with the company, Sara transformed the initiative into a commercial program launch. In 2022, Sara was promoted to Chief of Staff to facilitate the company vision by providing oversight to strategic business initiatives and be the go-to person for the executive team, senior leaders, board of directors, and the CEO. Before iRhythm, Sara spent 13 years at LifeScan, a diabetes company previously owned by JNJ. She held many leadership roles across a variety of functions including corporate finance, national payer account management, retail and ecommerce marketing, digital health, and strategic partnership development. Prior to JNJ Sara worked in international development and volunteered for the Peace Corps. Sara holds an International MBA from the University of South Carolina and a Certified Managerial Accountant credential.

Portrait

Brice Bobzien serves as Chief Financial Officer after joining the company in 2022. He most recently served as the Senior Vice President, Finance & Investor Relations of Dexcom, Inc., where he was responsible for global financial planning and analysis, investor relations, operations accounting, and global pricing strategy. Brice played an instrumental role in driving revenue growth initiatives that resulted in the company growing from $700 million to forecasted revenues of approximately $2.9 billion for fiscal year 2022. This growth included the scaling of the company’s global footprint, expanding beyond the United States and into more than 50 countries. During this time, Brice transformed the finance team into a world class organization designed to foster revenue growth and operational discipline. Brice’s track record includes more than 20 years of experience and increasing responsibility at leading medical device companies, including Zimmer Holdings, Inc., NuVasive, Inc. and Dexcom, Inc. Prior to these roles, Brice began his career in public accounting. Brice earned his Bachelor of Science degree in Business Administration from Indiana University, Fort Wayne, and is a Certified Public Accountant (non-practicing) in the state of Indiana.

Portrait

Mark Day serves as iRhythm’s Chief Technology Officer and was formerly the Executive Vice President of Research & Development. He has had other leadership roles in Research & Development and systems development since joining in 2007. Previously he worked in Medtronic’s Cardiac Rhythm Disease Management division. Prior to that, Mr. Day was Chief Technical Officer of CarePages, Inc., a blogging site for patients. Mr. Day has an M.B.A. in Marketing from the Wharton School, University of Pennsylvania, a Ph.D. in Computation Flow Physics from Stanford University, and also received an M.S. from Stanford, and a B.Sc. from Queen’s University, both in Mechanical Engineering.

Portrait

Douglas Devine joined iRhythm in 2020 as the Chief Financial Officer, and in 2021 was appointed the additional title of Chief Operating Officer. Doug brings more than 25 years of financial leadership experience to iRhythm, including a track record of success in fundraising, influencing business strategy, driving cost reductions, and implementing financial systems. He joins the company from GlobalFoundaries, a multi-billion dollar semiconductor foundry where he has been the Chief Financial Officer. Doug holds an MBA from the University of Michigan. He has also earned his CPA certification.

Portrait

Reyna Fernandez joined iRhythm in 2022 to lead the development and implementation of human resources strategies in support of the company’s global expansion plans. Previously, she served as Chief Human Resources Officer at Intersect ENT, Inc., where she was responsible for envisioning and implementing human resources strategies to support the company in becoming an integrated, world-class player in the therapeutics space. Reyna was instrumental in driving the continued growth of Intersect ENT through best-in-class talent acquisition, organizational effectiveness and human capital management functions. During her tenure with the company, she partnered with the CEO and executive leadership to create a performance culture focused on growth and operational excellence, transformed the HR organization to scale globally in line with business objectives, and worked strategically with the board of directors to align on compensation practices. Reyna brings global experience from roles with Endologix, Inc., Canon Medical Systems USA, Inc., Johnson & Johnson, and Bristol-Myers Squibb Company. Reyna earned her Master of Social Administration from Columbia University and a Bachelor of Arts degree in Cultural Anthropology from Haverford College in Pennsylvania.

Portrait

Mazi Kiani joined iRhythm in 2020 and serves as the Senior Vice President of Quality and Regulatory. Mazi brings more than 20 years of experience, including his role as Senior Vice President at Siemens Healthineers, leading the global Quality and Regulatory function for the ultrasound business area. Prior to that, Mazi held leadership and engineering roles at various leading healthcare companies, including Boston Scientific and Edwards Lifesciences. Mazi holds a B.S. in Chemical Engineering from the University of Washington.

Portrait

Sandrine Moirez joined iRhythm in 2022 and serves as iRhythm’s International General Manager. Prior to joining iRhythm, Sandrine spent 22 years at Medtronic where she held various leadership roles in Sales, Marketing, Product Development, Business Operations, and Business Transformation. In her most recent role at the Medtronic International European headquarters in Switzerland, she led the European Sales and Marketing efforts for the Spinal Technologies within the Cranial & Spinal Group, and was accountable for all commercial activities across the EMEA region. Sandrine holds a Ph.D. in Biomaterials from the University of Paris XIII, France. She also holds a Master of Science degree in Biomedical Engineering from Compiègne Technology University, France.

Patrick M. Murphy joined iRhythm in 2021 and serves as the Chief Legal Officer, he was formerly the General Counsel. Previously, he served as Executive Vice President and Chief Legal Officer of DexCom, Inc. since January 2020. Prior to that, he served as DexCom’s Senior Vice President, General Counsel and Chief Compliance Officer and Vice President, General Counsel and Chief Compliance Officer. Before that, Mr. Murphy was the Vice President of Legal Affairs at DexCom. Prior to joining DexCom, Mr. Murphy was a partner at Stradling Yocca Carlson & Rauth law firm, where he specialized in corporate finance, mergers and acquisitions and general corporate matters. Mr. Murphy received a J.D. from the St. Louis University School of Law and a B.S. from the Truman State University. Mr. Murphy is a member of the State Bar of California.

Portrait

Chad Patterson joined iRhythm as Chief Commercial Officer in 2022. Chad previously served as Chief Marketing Officer of Dexcom, Inc., where he was responsible for global product management, design, clinical education, customer experience, research, public relations, and healthcare provider and direct-to-consumer marketing. He played an instrumental role in driving revenue growth initiatives that resulted in the company growing from $400 million to forecasted revenues of approximately $2.9 billion for fiscal year 2022 as well as expanding beyond the United States and into more than 50 countries generating more than $750 million in annual international sales. Earlier in his career, Chad served in various global strategic brand and product management roles with Nestlé in both the US and Switzerland. In his last post, he was responsible for developing and executing the 10-year global business strategy of Nestle’s fastest growing global brand, Coffee-Mate®. Chad earned his Master of Business Administration from University of Southern California, Marshall School of Business, and a Bachelor of Arts degree from Gonzaga University, where he played Division I soccer.

Portrait

Sumi Shrishrimal joined iRhythm in May 2022 and serves as the Executive Vice President and Chief Risk Officer. Prior to joining iRhythm, Sumi served as Chief Risk Officer at Dexcom where she was responsible for oversight and development of the Enterprise Risk Management program, the Global Compliance & Privacy program and the Internal Audit function. She also served as a strategic business partner for management to ensure that the company’s culture maintained its unwavering commitment to ethics and compliance. Before Dexcom, Sumi was the Vice President of Internal Audit at NuVasive. Prior to NuVasive, Sumi held multiple leadership positions in internal audit and accounting within the education and financial services industries with over 14 years of experience. Sumi started her career with PricewaterhouseCoopers where she consulted on a wide range of projects in the Assurance Business Advisory Services and the Transaction Services groups. Sumi is a Certified Public Accountant in California and a Certified Information Systems Auditor. She holds a Bachelor’s in Accounting and Information Systems from the University of Mumbai.

Portrait

Dr. Turakhia, who joined as CMO and CSO in 2022, is an internationally recognized cardiac electrophysiologist and leader in digital health and heart rhythm care. He is Professor of Medicine (on leave) at the Stanford University School of Medicine. Trained in computer science, medicine, biostatistics, and research, he brings over 20 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation, and the creation and commercialization of digital health products.

As Co-Founder of the Stanford Center for Digital Health, he has led several large-scale trials of digital health tools and wearables for heart disease, including the landmark Apple Heart Study. In academic and industry roles, he has led teams to build and commercialize software-enabled disease management and remote patient monitoring programs for heart disease with several recent exits. An elected member of the American Society of Clinical Investigation, Dr. Turakhia has authored over 300 publications and has received over $40 million in research funding. Over the last 20 years, he has had several dozen leadership and clinical practice guideline author roles in the Heart Rhythm Society, American Heart Association, American College of Cardiology, and European Society of Cardiology. He completed his bachelor’s degree at the University of California (UC) Berkeley, MD and master’s degrees at UCSF, and clinical training at Harvard’s Brigham & Women’s Hospital and UCSF. For 14 years, he served as Chief of Cardiac Electrophysiology at the VA Palo Alto Health Care System, where he still practices and performs catheter ablation and device implantation.

Portrait

Daniel G. Wilson has served as iRhythm’s Executive Vice President of Strategy, Corporate Development and Investor Relations since June 2019. Previously, he served as Director and Head of Business Development at Penumbra, Inc., a global healthcare company focused on innovative therapies. Prior to Penumbra, he held various positions at J.P. Morgan over a 10-year tenure, most recently as Executive Director in the Healthcare Investment Banking group focused on digital health, medical technology and emerging healthcare companies. Earlier in his career, he held various positions in Piper Jaffray’s Healthcare Investment Banking group. He started his career at KPMG as an Audit Associate. Mr. Wilson has a B.S. in Business Administration from California Polytechnic State University at San Luis Obispo.

Email Alerts

Sign up to receive e-mail alerts whenever iRhythm posts new information to the site.